ICC Hears Chinese-Korean Biopharma Dispute

. A Korean biopharmaceutical company is facing an ICC lodged by its Chinese partner in a US$81 million collaboration to develop a treatment for autoimmune diseases – and says it has filed a counterclaim to terminate the partnership

Learn More

Leave a Comment

Your email address will not be published. Required fields are marked *

Scroll to Top